ReviewInternational journal of nephrology and renovascular disease2022
Obstacles to Early Diagnosis and Treatment of Pruritus in Patients with Chronic Kidney Disease: Current Perspectives.
Review in International journal of nephrology and renovascular disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.
- Prevalence and influencing factors of pruritus in maintenance hemodialysis patients in China: a meta-analysis.BMC nephrology · 2025Pooled it
- Exploratory Analysis of Pruritus and Sleep Outcomes After LCR35 Supplementation in Maintenance Hemodialysis: A Randomized, Open-Label Controlled Study.Life (Basel, Switzerland) · 2026Article
- Difelikefalin in Chinese patients with chronic kidney disease-associated pruritus.Clinical kidney journal · 2026Article
- Association of Chronic Kidney Disease-Associated Pruritus With the Sleep Disturbance, Depression, Pain, Anxiety, and Low Energy/Fatigue Symptom Cluster: A Retrospective Cohort Study.Kidney medicine · 2026Article
- CKD-Associated Pruritus: A Patient-Centered Approach to Reduce Symptom Burden.Kidney medicine · 2025Review
- Real-world safety of difelikefalin for chronic kidney disease-associated pruritus: initial insights from a European managed access programme.Clinical kidney journal · 2025Article
- The efficacy and safety of kappa opioid receptor (KOR) agonists in patients with uraemic pruritus: a systematic review and network meta-analysis.Clinical kidney journal · 2025Article
- Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study.BMC nephrology · 2025Article
- Efficacy and safety of HSK21542 for pruritus management in hemodialysis patients: a multicenter, randomized, double-blind, placebo-controlled trial.Frontiers in pharmacology · 2025Article
- Article
- Chronic Kidney Disease-Associated Pruritus Burden: A Patient Survey Study.Kidney medicine · 2024Article
- Chronic kidney disease-associated pruritus and quality of life with difelikefalin treatment: aClinical kidney journal · 2024Article
- Pathways for Diagnosing and Treating CKD-Associated Pruritus: A Narrative Review.Canadian journal of kidney health and disease · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease-associated pruritus (CKD-aP) is a common condition amongst patients with advanced chronic kidney disease (CKD). Several studies have confirmed that more than four out of ten early-stage CKD patients suffer from this condition, while its prevalence among CKD patients on dialysis reaches up to seven out of ten. It is noted to be associated with other disabling symptoms and serious outcomes. It has significant impact on sleep, mood, daily activities, and quality of life of CKD patients, and increased mortality risk of patients on hemodialysis. The Dialysis Outcomes and Practice Patterns Study found 17% higher mortality among patients with moderate to extreme pruritus compared with patients with no or mild pruritus. Despite its high prevalence, ill-effect, and suffering associated with it, CKD-aP remains surprisingly under-reported on the patient's part and under-recognized by the healthcare team. Even upon being noticed, it remains unattended and poorly treated. Its etiopathogenesis is complex and not fully understood. Many treatment options are available but good quality evidence about most of those is absent, and to date, only two medications are approved for use in this condition. While a validated guideline is very much required for the benefit of the patients and caretakers, further research on several aspects of this issue is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.